Modality
Peptide
MOA
BCMA ADC
Target
PD-L1
Pathway
Incretin
MSASDMD
Development Pipeline
Preclinical
Sep 2025
→ Aug 2030
PreclinicalCurrent
NCT05363043
2,004 pts·MS
2025-09→2030-08·Recruiting
2,004 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-08-174.4y awayInterim· MS
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Recruit…
Catalysts
Interim
2030-08-17 · 4.4y away
MS
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05363043 | Preclinical | MS | Recruiting | 2004 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 | |
| MRU-8112 | Merus | Preclinical | PD-L1 | |
| Tixatapinarof | Recursion | Approved | FGFR |